Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168566 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Teligene US.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT05168566 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Teligene US. The registered enrollment target is 99 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05168566, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Teligene US.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Conditions Studied
Interventions
- DRUG Sutetinib Maleate Capsule
Study Locations (20)
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
- Beijing Chest Hospital - Beijing
Henan
- Henan Cancer Hospital - Zhengzhou
- The First Affiliated Hospital of Zhengzhou University - Zhengzhou
California
- OPN Healthcare, Inc. - Glendale
Georgia
- University Cancer & Blood Center - Athens
Kentucky
- Baptist Health - Louisville
Maryland
- University of Maryland Medical Center - Baltimore
North Carolina
- FirstHealth Cancer Center - Pinehurst
Texas
- The University of Texas- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05168566
The ClinicalTrials.gov registry entry for NCT05168566 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Teligene US, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sutetinib Maleate Capsule is the first listed.
NCT05168566 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Beijing Municipality, Henan, California.
Frequently Asked Questions
What is clinical trial NCT05168566 about?
NCT05168566 is a clinical study titled "Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer". This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
What is the current status of trial NCT05168566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2022-09-01. Estimated completion is 2026-06.
What conditions does trial NCT05168566 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05168566?
The interventions under investigation include: Sutetinib Maleate Capsule (DRUG).
Who is sponsoring clinical trial NCT05168566?
This trial is sponsored by Teligene US, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05168566 being conducted?
This trial has 20 study locations across California, Georgia, Kentucky, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.